Home
/
OCULAR THERAPEUTIX, INC
/
Financials
/
Quarterly
OCULAR THERAPEUTIX, INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that OCULAR THERAPEUTIX, INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2018
Sep 30, 2018
$498.0K
Nov 7, 2018
Q2
2018
Jun 30, 2018
$648.0K
Aug 7, 2018
Q1
2018
Mar 31, 2018
$340.0K
May 8, 2018
Q3
2018
Sep 30, 2017
$523.0K
Nov 7, 2018
Q2
2018
Jun 30, 2017
$438.0K
Aug 7, 2018
Q1
2018
Mar 31, 2017
$475.0K
May 8, 2018
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$14.54M
Nov 4, 2025
Q2
2025
Jun 30, 2025
$13.46M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$10.70M
May 5, 2025
Q3
2025
Sep 30, 2024
$15.43M
Nov 4, 2025
Q2
2025
Jun 30, 2024
$16.44M
Aug 5, 2025
Q1
2025
Mar 31, 2024
$14.77M
May 5, 2025
Q3
2024
Sep 30, 2023
$15.08M
Nov 14, 2024
Q2
2024
Jun 30, 2023
$15.19M
Aug 7, 2024
Q1
2024
Mar 31, 2023
$13.37M
May 7, 2024
Q3
2023
Sep 30, 2022
$11.97M
Nov 7, 2023
Q2
2023
Jun 30, 2022
$12.27M
Aug 7, 2023
Q1
2023
Mar 31, 2022
$13.19M
May 8, 2023
Q3
2022
Sep 30, 2021
$12.15M
Nov 7, 2022
Q2
2022
Jun 30, 2021
$11.72M
Aug 8, 2022
Q1
2022
Mar 31, 2021
$7.34M
May 9, 2022
Q3
2021
Sep 30, 2020
$5.88M
Nov 8, 2021
Q2
2021
Jun 30, 2020
$1.57M
Aug 9, 2021
Q1
2021
Mar 31, 2020
$2.61M
May 5, 2021
Q3
2020
Sep 30, 2019
$829.0K
Nov 5, 2020
Q2
2020
Jun 30, 2019
$650.0K
Aug 7, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2017
Sep 30, 2017
$523.0K
Nov 7, 2017
Q2
2017
Jun 30, 2017
$438.0K
Aug 8, 2017
Q1
2017
Mar 31, 2017
$475.0K
May 5, 2017
Q3
2017
Sep 30, 2016
$477.0K
Nov 7, 2017
Q2
2016
Jun 30, 2016
$441.0K
Aug 9, 2016
Q1
2017
Mar 31, 2016
$458.0K
May 5, 2017
Q3
2016
Sep 30, 2015
$429.0K
Nov 9, 2016
Q2
2016
Jun 30, 2015
$459.0K
Aug 9, 2016
Q1
2016
Mar 31, 2015
$426.0K
May 10, 2016
Q3
2015
Sep 30, 2014
$143.0K
Nov 10, 2015
Q2
2015
Jun 30, 2014
$97.0K
Aug 10, 2015
Q1
2015
Mar 31, 2014
$27.0K
May 15, 2015
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($69.42M)
Nov 4, 2025
Q2
2025
Jun 30, 2025
($67.81M)
Aug 5, 2025
Q3
2025
Jun 30, 2025
($67.81M)
Nov 4, 2025
Q1
2025
Mar 31, 2025
($64.05M)
May 5, 2025
Q2
2025
Mar 31, 2025
($64.05M)
Aug 5, 2025
Q3
2025
Mar 31, 2025
($64.05M)
Nov 4, 2025
Q3
2025
Sep 30, 2024
($36.49M)
Nov 4, 2025
Q3
2025
Jun 30, 2024
($43.78M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($43.78M)
Aug 5, 2025
Q3
2025
Mar 31, 2024
($64.85M)
Nov 4, 2025
Q2
2025
Mar 31, 2024
($64.85M)
Aug 5, 2025
Q1
2025
Mar 31, 2024
($64.85M)
May 5, 2025
Q3
2024
Sep 30, 2023
($516.0K)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($20.68M)
Aug 7, 2024
Q3
2024
Jun 30, 2023
($20.68M)
Nov 14, 2024
Q3
2024
Mar 31, 2023
($30.32M)
Nov 14, 2024
Q2
2024
Mar 31, 2023
($30.32M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($30.32M)
May 7, 2024
Q3
2023
Sep 30, 2022
($24.19M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($18.77M)
Aug 7, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($68.70M)
Nov 4, 2025
Q2
2025
Jun 30, 2025
($67.64M)
Aug 5, 2025
Q1
2025
Mar 31, 2025
($63.92M)
May 5, 2025
Q3
2025
Sep 30, 2024
($46.00M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($43.59M)
Aug 5, 2025
Q1
2025
Mar 31, 2024
($31.62M)
May 5, 2025
Q3
2024
Sep 30, 2023
($19.21M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($20.57M)
Aug 7, 2024
Q1
2024
Mar 31, 2023
($22.55M)
May 7, 2024
Q3
2023
Sep 30, 2022
($21.54M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($19.92M)
Aug 7, 2023
Q1
2023
Mar 31, 2022
($17.83M)
May 8, 2023
Q3
2022
Sep 30, 2021
($19.53M)
Nov 7, 2022
Q2
2022
Jun 30, 2021
($20.23M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
($20.23M)
May 9, 2022
Q3
2021
Sep 30, 2020
($14.01M)
Nov 8, 2021
Q2
2021
Jun 30, 2020
($17.88M)
Aug 9, 2021
Q1
2021
Mar 31, 2020
($16.61M)
May 5, 2021
Q3
2020
Sep 30, 2019
($23.14M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($21.60M)
Aug 7, 2020